Outline of Presentation

- FY16 Budget and FY17 Proposal
- PMI for Oncology
- Vice President’s Cancer Initiative
- Other Updates
Outlook for Cancer Research Funding

- Strong bipartisan support for NCI/NIH
  - Key role of advocacy
  - Faster progress for patients
- Potential for continuing increases in Federal cancer research funding
- Coordination with private funding efforts
NCI FY16 Appropriation: A ~5% increase

- ~$265 million total increase
- $70 million for the President’s Precision Medicine Initiative in Oncology (PMI-O)
- $195 million: Mandatory increases + new initiatives
NCI FY16 Appropriation Increase: Non-PMI-O Funding

- $195 million: Non-PMI-O increase
- ~$50 million for increased fixed costs (lights, etc.)
- $10 million: Increase base for Cancer Center Support Grants
- $55 million: jump-start Vice President’s Cancer Initiative
- $80 million: ~$50 million for type 2 RPG pool, ~$30 million for new & competing RPG pool
NCI BUDGET 2005 – 2015: A PERIOD OF LEVEL BUDGETS & PROGRESSIVELY DECREASING PURCHASING POWER

FY 2016 & 2017: AN ENCOURAGING TREND

The dashed line at approximately $3.3 billion indicates that the inflation-adjusted FY 2017 proposed budget is similar to the FY 2000 budget.

Source: NCI Office of Budget and Finance
Outline of Presentation

- FY16 Budget and FY17 Proposal
- PMI for Oncology
- Vice President’s Cancer Initiative
- Other Updates
Components of PMI-Oncology

- Developing and expanding clinical therapy trials in precision oncology
- Improving predictive oncology: by overcoming drug resistance, determining effective combination targeted therapy, and advancing immunotherapy
- Creating a new array of laboratory models, to increase understanding of cancer biology and achieve the goals of predictive oncology
- Building a national cancer knowledge system that integrates cancer genomic information, clinical information, and laboratory model information
NCI MATCH Current Status

- Launched August 2015
- Nearly 800 patients registered in 3 months
- Protocol directed pause in accrual to screening (Nov 2015) to evaluate early results and make needed adjustments
  - Tumor histologic types
  - Match rate (current 10 arms and planned arms)
  - Laboratory performance
  - Biopsy quality
- Trial “arms” remain open for those who matched
- Continuing the process of activating new arms
  - Anticipate 20-24 arms open by May 2016
- Adding laboratory capacity
  - Preanalytics
  - Sequencing
NCI MATCH Protocols in Development

- KIT sensitizing mutation
- PTEN loss
- PIK3Ca mutation
- SMO/PTCH1 mutation
- TORC1/2 mutation
- TSC1/2 mutation
- DDR2 mutation
- NF1 mutation
- GNAQ/GNA11 mutation
- FGFR abnormalities
- AKT mutations
Outline of Presentation

- FY16 Budget and FY17 Proposal
- PMI for Oncology
- Vice President’s Cancer Initiative
- Other Updates
The Vice President’s Cancer Initiative--
A preliminary draft of ideas

- Accelerate progress in cancer, including prevention & screening
  - From cutting edge to wider uptake of standard of care
- Encourage greater cooperation and breaking down silos
  - Within and between academia, government, and private sector
- Importance of data sharing
Proposed for Prevention, Screening, and Implementation

- Developing preventive vaccines against infectious and non-infectious targets
- Developing screening tests with body fluid samples (e.g., blood, saliva)
- Increasing uptake of standard of care for prevention, screening, and treatment
Proposed for Cancer Treatment Trials

- Increase immunotherapy trials and combination therapy trials
- Increase participation in clinical trials
- Develop an NCI drug formulary from many companies to facilitate preclinical and trial access to investigational agents
Other Proposed Research

- Develop drugs for pediatric cancer
- Increase genomic analysis of tumor cells and stromal cells
- Develop an “exceptional opportunities fund”
Researchers and other stakeholders

Evaluate the current proposal: science, collaboration, public-private partnerships, etc.

Consider other research opportunities

Report to NCAB at June 2016 meeting
Outline of Presentation

- FY16 Budget and FY17 Proposal
- PMI for Oncology
- Vice President’s Cancer Initiative
- Other Updates
Other Updates

- NCAB Cancer Centers Report and Follow Up
- NCAB SPORE Working Group Report
- EDRN RFA
- ETCTN Supplements
- Chemical Biology Consortium
### The New Base Awards – Increases for 21/69 Cancer Centers

#### BASIC (2/7; 29%)

<table>
<thead>
<tr>
<th>Center</th>
<th>FY15 Budget</th>
<th>Proposed Base FY16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purdue</td>
<td>1,060,500</td>
<td>1,200,000</td>
</tr>
<tr>
<td>Jackson</td>
<td>1,156,367</td>
<td>1,200,000</td>
</tr>
</tbody>
</table>

#### CLINICAL (12/17; 71%)

<table>
<thead>
<tr>
<th>Center</th>
<th>FY15 Budget</th>
<th>Proposed Base FY16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indiana</td>
<td>999,867</td>
<td>1,400,000</td>
</tr>
<tr>
<td>Emory</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>Mt. Sinai</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>MUSC</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>Oregon</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>Hawaii</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>Kansas</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>Kentucky</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>Maryland</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>Nebraska</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>VCU</td>
<td>1,000,000</td>
<td>1,400,000</td>
</tr>
<tr>
<td>UT-SA</td>
<td>1,204,014</td>
<td>1,400,000</td>
</tr>
</tbody>
</table>

#### COMPREHENSIVE (7/45; 16%)

<table>
<thead>
<tr>
<th>Center</th>
<th>FY15 Budget</th>
<th>Proposed Base FY16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wake</td>
<td>1,000,000</td>
<td>1,500,000</td>
</tr>
<tr>
<td>UT-SW</td>
<td>1,000,000</td>
<td>1,500,000</td>
</tr>
<tr>
<td>Utah</td>
<td>1,111,000</td>
<td>1,500,000</td>
</tr>
<tr>
<td>Arizona</td>
<td>1,257,443</td>
<td>1,500,000</td>
</tr>
<tr>
<td>New Mexico</td>
<td>1,272,293</td>
<td>1,500,000</td>
</tr>
<tr>
<td>City of Hope</td>
<td>1,300,357</td>
<td>1,500,000</td>
</tr>
<tr>
<td>Georgetown</td>
<td>1,454,514</td>
<td>1,500,000</td>
</tr>
</tbody>
</table>
Other Updates

- NCAB Cancer Centers Report and Follow Up
- NCAB SPORE Working Group Report
- EDRN RFA
- ETCTN Supplements
- Chemical Biology Consortium